Characteristics of surgical prosthetic heart valves and problems around labeling: A document from the European Association for Cardio-Thoracic Surgery (EACTS)-The Society of Thoracic Surgeons (STS)-American Association for Thoracic Surgery (AATS) Valve Labelling Task Force.
Bioprosthesis
/ standards
Cardiology
/ standards
Clinical Decision-Making
Consensus
Consumer Product Safety
/ standards
Equipment Failure Analysis
/ standards
Heart Valve Prosthesis
/ standards
Heart Valve Prosthesis Implantation
/ adverse effects
Humans
Patient Selection
Product Labeling
/ standards
Prosthesis Design
/ standards
Prosthesis Failure
Societies, Medical
International standard
aortic valve replacement
device approval
labeling
lnternational Organization for Standardization (ISO)
mitral valve replacement
objective performance criteria (OPC)
prosthesis–patient mismatch (PPM)
prosthetic heart valve
regulation
sizing
surgical prosthetic heart valve (SHV)
valve performance
Journal
The Journal of thoracic and cardiovascular surgery
ISSN: 1097-685X
Titre abrégé: J Thorac Cardiovasc Surg
Pays: United States
ID NLM: 0376343
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
02
11
2018
revised:
08
01
2019
accepted:
17
01
2019
pubmed:
16
5
2019
medline:
3
3
2020
entrez:
16
5
2019
Statut:
ppublish
Résumé
Intraoperative surgical prosthetic heart valve (SHV) choice is a key determinant of successful surgery and positive postoperative outcomes. Currently, many controversies exist around the sizing and labeling of SHVs rendering the comparison of different valves difficult. To explore solutions, an expert Valve Labelling Task Force was jointly initiated by the European Association for Cardio-Thoracic Surgery (EACTS), The Society of Thoracic Surgeons (STS) and the American Association for Thoracic Surgery (AATS). The EACTS-STS-AATS Valve Labelling Task Force, comprising cardiac surgeons, cardiologists, engineers, regulators and representatives from the International Organization for Standardization (ISO), and major valve manufacturers, held its first in-person meeting in February 2018 in Paris, France. This article was derived from the meeting's discussions. The Task Force identified the following areas for improvement and clarification: reporting of physical dimensions and characteristics of SHVs determining and labeling of SHV size, in vivo and in vitro testing, and reporting of SHV hemodynamic performance and thrombogenicity. Furthermore, a thorough understanding of the regulatory background and the role of the applicable ISO standards, together with close cooperation between all stakeholders (including regulatory and standard- setting bodies), is necessary to improve the current situation. Cardiac surgeons should be provided with appropriate information to allow for optimal SHV choice. This first article from the EACTS-STS-AATS Valve Labelling Task Force summarizes the background of SHV sizing and labeling and identifies the most important elements where further standardization is necessary.
Identifiants
pubmed: 31084981
pii: S0022-5223(19)30775-5
doi: 10.1016/j.jtcvs.2019.04.001
pii:
doi:
Types de publication
Consensus Development Conference
Journal Article
Practice Guideline
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1041-1054Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2019 The Society of Thoracic Surgeons, The American Association for Thoracic Surgery, and the European Association for Cardio-Thoracic Surgery. Published by Elsevier Inc. All rights reserved.